AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 104 filers reported holding AKERO THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,698 | -33.9% | 33,582 | -38.9% | 0.00% | -50.0% |
Q2 2023 | $2,567 | +782.1% | 55,001 | +622.4% | 0.00% | – |
Q1 2023 | $291 | -79.8% | 7,614 | -71.0% | 0.00% | -100.0% |
Q4 2022 | $1,440 | -99.9% | 26,286 | -66.5% | 0.00% | -33.3% |
Q3 2022 | $2,668,000 | – | 78,371 | +75988.3% | 0.00% | – |
Q2 2022 | $0 | -100.0% | 103 | -39.8% | 0.00% | – |
Q1 2022 | $2,000 | -99.3% | 171 | -98.5% | 0.00% | – |
Q3 2021 | $295,000 | -2.0% | 11,642 | -4.1% | 0.00% | – |
Q2 2021 | $301,000 | -84.8% | 12,142 | -82.2% | 0.00% | -100.0% |
Q1 2021 | $1,974,000 | – | 68,063 | +340215.0% | 0.00% | – |
Q2 2020 | $0 | – | 20 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 5,830,203 | $168,435,000 | 13.00% |
venBio Partners LLC | 2,444,311 | $63,063,000 | 5.57% |
Versant Venture Management, LLC | 777,727 | $20,065,000 | 2.08% |
Vivo Capital, LLC | 633,426 | $16,342,000 | 0.73% |
Redmile Group, LLC | 2,322,557 | $59,922,000 | 0.73% |
Boxer Capital, LLC | 831,495 | $21,453,000 | 0.69% |
Integral Health Asset Management, LLC | 85,000 | $2,193,000 | 0.65% |
SILVERARC CAPITAL MANAGEMENT, LLC | 35,179 | $908,000 | 0.53% |
HighVista Strategies LLC | 27,739 | $716,000 | 0.46% |
Cormorant Asset Management, LP | 742,549 | $19,158,000 | 0.46% |